Pfizer Limited
Walton Oaks, Dorking Road, Walton on the Hill,
Tadworth, Surrey KT20 7NS, UK
Telephone: +44 (0)1304 616161

Worldwide Biopharmaceutical Businesses

December 8, 2011

Torisel®

(temsirolimus, concentrate and diluent for solution for infusion.)

CHMP recommends that health care professionals visually inspect Torisel diluent to exclude the presence of particulate matter, prior to administration.

Dear Healthcare Professional:

Summary

This letter is to inform you of the importance of visually inspecting the diluent vial provided within the pack prior to mixing it with Torisel® (temsirolimus) concentrate, in the preparation of the intravenous solution. This communication has been triggered by the European Medicines Agency upon request of the European Commission because of significant GMP issues identified at the manufacturing site (Ben Venue Laboratories, BVL) where the diluent used with Torisel has been produced. There are no issues reported with the active ingredient of Torisel, which is manufactured at a different facility.

The communication of this information has been agreed with the European Medicines Agency (EMA) and the Irish Medicines Board.

Recommendation to healthcare professionals

- **Healthcare professionals should visually inspect the Torisel diluent vials in order to exclude the potential presence of particulate matter before dilution and administration of the reconstituted medicinal product, and therefore to minimise any relevant risk.**

- Torisel is a concentrate for infusion that is supplied with a diluent. The concentrate is a clear, colourless to light-yellow solution. The diluent is a clear to slightly turbid, light-yellow to yellow solution. **The solution should be free from visible particulates**.

- **Always follow carefully the administration instructions provided in the Summary of Product Characteristics and in the Package Insert.**

- **If you note anything unusual in the diluent vial please do not use the vial**. Healthcare providers should also report any evidence of particulate matter noted in the Torisel diluent with actions taken. *Please call Medical Information at Pfizer Limited: 1800 633363*).

Registered in England: No 526209
Registered Office: Ramsgate Road
Sandwich, Kent CT13 9NJ, UK

Further information on the safety concern

The EMA carried out an inspection at the production site of the Torisel diluent in November 2011, at which it made observations relating to the presence of particulate matter.

Background information on Torisel

Torisel is a medicinal product containing temsirolimus. Torisel is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. Torisel is also indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma [MCL] (see section 4.1 of the Summary Product Characteristics).

From 19 November 2007 (International Birth Date [IBD]) through 31 November 2011, the worldwide estimated exposure to Torisel is approximately 25,000 including post-marketing and clinical trials patients. The marketing authorization number is EU/1/07/424/001.

REPORTING RECOMMENDATIONS

Healthcare professionals should report any serious adverse events suspected to be associated with the use of Torisel to Pfizer at 1800 633363. Alternatively, this information may be reported to the IMB by calling (01) 6764971, using on-line reporting forms at: www.imb.ie or by emailing imbpharmacovigilance@imb.ie.

For further information or any questions on the use of Torisel, please contact Medical Information at Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS or Tel.: 1800 633363.

Sincerely,

Dr. Hakan Granlund
Country Medical Director
Pfizer Healthcare Ireland